TABLE 1.

Delphi process results for the original survey*

				Consensus (all others voted neutral)
Question	Intraoperative/In‐office use	Question/statement	Resurveyed (yes/no)	Agree	Disagree	Accepted (yes/no)
1	Intraoperative	Steroid‐eluting stent placement should only be considered in sinus surgery for chronic rhinosinusitis with nasal polyps	Yes	8%	67%	No
2	Intraoperative	Steroid‐eluting stent placement could be considered in sinus surgery for chronic rhinosinusitis without nasal polyps	Yes	92%	8%	Yes
3	Intraoperative	Steroid‐eluting stent placement should be considered in sinus surgery for patients intolerant of oral steroids	No	92%	8%	Yes
4	Intraoperative	If a patient has diabetes, then steroid‐eluting stents could be considered instead of oral steroids after endoscopic sinus surgery	No	92%	0%	Yes
5	Intraoperative	For extended frontal sinus approaches/surgeries, steroid‐eluting stents could be considered	No	100%	0%	Yes
6	Intraoperative	No more than 2 steroid‐eluting stents should be placed in each sinonasal cavity	Yes	50%	0%	No
7	Intraoperative	For patients with poor compliance with postoperative rinses, steroid‐eluting stent placement could be considered in primary sinus surgery	No	58%	17%	No
8	Intraoperative	Propel should never be placed in an acutely infected field	Yes	42%	17%	No
9	In‐office	SINUVA placement could be considered for ethmoid or frontal recess recurrent polyps after surgery as an alternative to biologic therapy	No	75%	0%	No
10	In‐office	If a patient has recurrent stenosis, then a steroid‐eluting stent could be used in the office	No	92%	0%	Yes
11	In‐office	SINUVA is most optimally positioned only if total ethmoidectomy has been performed	Yes	83 %	17%	Yes
12	In‐office	PROPEL should be removed within 21 days of surgery	No	50%	17%	No

*Shaded statements reached consensus and were accepted (n = 14). Note: Question 2 was resurveyed despite reaching agreement as it was directly correlated with question 1.